- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00263198
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
Phase II Study of the Combination of PTK787/ZK222584 and Letrozole in Postmenopausal Women With Advanced Hormone Receptor Positive Breast Cancer
Přehled studie
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Missouri
-
St. Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Postmenopausal women with metastatic breast cancer, or loco-regional disease recurrence not amenable to treatment by surgery or radiotherapy.
Postmenopausal status will be defined by any of the following criteria:
- no spontaneous menses for at least 5 years
- spontaneous menses within the past 5 years but amenorrheic for at least 12 months and estradiol and/or FSH values in the postmenopausal range (while off aromatase inhibitor therapy; levels can have been taken while on tamoxifen but in this case estradiol should be the parameter assessed)
- bilateral oophorectomy
- radiation castration and amenorrheic for at least 3 months
- the use of an LHRH agonist throughout the duration of the trial (for example goserelin 3.6 mg s.c. monthly)
- Age ≥ 18 years old
- Patients whose tumors are either estrogen-receptor (ER) and/or progesterone-receptor (PgR) positive (10% or more infiltrating cancer cells exhibiting nuclear staining). Patients will be regarded as ER or PgR positive as long as at least one of the tissues assessed was positive. A positive biochemical test is also acceptable.
- Patients must have a WHO Performance Status Grade 0-2
- Newly diagnosed patients who are initiating first line treatment or those patients with known disease who have shown resistance to anti- estrogen therapy (tamoxifen or toremifine).
- Patients currently receiving letrozole or alternative aromatase inhibitors as initial therapy who are without evidence of progressive disease are eligible.
- Patients with bone-only metastasis are eligible.
Laboratory values ≤ 2 weeks prior to randomization:
- Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L (≥ 1500/mm3)
- Platelets (PLT) ≥ 100 x 109/L (≥ 100,000/mm3)
- Hemoglobin (Hgb) ≥ 9 g/dL
- Serum creatinine ≤ 1.5 ULN
- Serum bilirubin ≤ 1.5 ULN
- Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3.0 x ULN (≤ 5 x ULN if liver metastases present)
Negative for proteinuria based on dip stick reading OR, if documentation of +1 result for protein on dip stick reading, then total urinary protein
- 500 mg and measured creatinine clearance (CrCl) ≥ 50 mL/min from a 24- hour urine collection
- Life expectancy ≥ 12 weeks
- Written informed consent obtained according to local guidelines
Exclusion Criteria:
- Patients with tumors which are both estrogen and progesterone receptor negative, or estrogen receptor negative and progesterone receptor unknown or estrogen receptor unknown and progesterone receptor negative
- Patients with a history of adrenalectomy or hypophysectomy
- Patients who developed progressive disease while being treated with an aromatase inhibitor.
Patients with any of the following:
- Absolute Neutrophil Count < 1.5 x 109/L
- Hemoglobin < 9 g/dl
- Platelet count < 100 x 109/L
- AST and ALT > 3 times the upper limit of normal or > 5 times the upper limit of normal if liver metastasis are present
- Bilirubin > 1.5 upper limit of normal
- Creatinine > 1.5 x upper limit of normal
- Calcium > 11.6 mg/dL
- History or presence of central nervous system (CNS) disease (i.e., primary brain tumor, malignant seizures, CNS metastases or carcinomatous meningitis)
- Patients with a history of another primary malignancy ≤ 5 years that has not been treated for curative intent or that the chance of long term remission is judged to be less than 50%.
- Prior chemotherapy <3 weeks prior to registration and/or randomization. Patients must have recovered from all therapy-related toxicities
- Prior biologic or immunotherapy ≤ 2 weeks prior to registration and/or randomization. Patients must have recovered from all therapy-related toxicities
- Patients with a history of treatment with Fulvestrant or Trastuzumab < 6 months prior to registration. Patients must have recovered from all therapy- related toxicities in order to be enrolled.
- Prior full field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior to randomization. Patients must have recovered from all therapy-related toxicities. The site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease
- Major surgery (e.g., laparotomy) ≤ 4 weeks prior to randomization. Minor surgery ≤ 2 weeks prior to randomization. Insertion of a vascular access device is not considered major or minor surgery in this regard. Patients must have recovered from all surgery-related toxicities
- Patients who have received investigational drugs ≤ 4 weeks prior to registration and/or randomization
- Prior therapy with anti-VEGF agents
- Peripheral neuropathy with functional impairment ≥ CTC grade 2 neuropathy, regardless of causality
- Pleural effusion or ascites that causes respiratory compromise (≥ CTC grade 2 dyspnea)
Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:
- Uncontrolled high blood pressure (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 95 mmHg), history of labile hypertension, or history of poor compliance with an antihypertensive regimen
- Unstable angina pectoris
- Symptomatic congestive heart failure
- Myocardial infarction ≤ 6 months prior to registration and/or randomization
- Serious uncontrolled cardiac arrhythmia
- Uncontrolled diabetes (fasting blood sugar > 300 mg/dl)
- Active or uncontrolled infection
- Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
- Patients with prolonged QTc > 470 msec on EKG. All patients with a history of congenital or acquired long QTc syndrome.
- Chronic renal disease
- Acute or chronic liver disease (e.g., hepatitis, cirrhosis)
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PTK787/ZK 222584 (i.e., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow the tablets)
Patients with confirmed diagnosis of human immunodeficiency virus (HIV) infection are excluded at the investigator's discretion if it is felt that:
1) a potential drug interaction between PTK787/ZK 222584 and any of the patient's anti-HIV medications could influence the efficacy of the anti-HIV medication, or 2) it may place the patient at risk due to the pharmacologic activity of PTK787/ZK 222584. Please refer to appendix for a list of examples of substrates of human liver microsomal P450 enzymes
- Patients who are taking therapeutic warfarin sodium (Coumadin) or similar oral anticoagulants that are metabolized by the cytochrome P450 system. Heparin in any formulation is allowed. Please refer to appendix for a list of examples of substrates of human liver microsomal P450 enzymes
- Patients on P450 enzyme inducing anti-epileptics
- Patients who are unwilling or unable to comply with protocol requirements.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Letrozole + PTK787/ZK222584
Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part) Start cycle 1 with:
Subsequent cycles:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Assess the effect of the combination of letrozole & PTK787/ZK222584 on disease progression.
Časové okno: 24 weeks after starting PTK787/ZK222584
|
24 weeks after starting PTK787/ZK222584
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Evaluate the response rate (CR and PR)
Časové okno: Completion of treatment
|
Completion of treatment
|
|
Evaluate the safety and tolerability of the combination of drugs
Časové okno: 30 days after completion of study treatment
|
30 days after completion of study treatment
|
|
Evaluate the pharmacokinetic profiles of the combination of drugs
Časové okno: Cycle 3 Day 1
|
Cycle 3 Day 1
|
|
Evaluate the modulation of tumor blood flow and blood vessel permeability in response to PTK787/ZK222584 when administered in combination with letrozole using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Časové okno: Cycle 1 Day 28
|
Cycle 1 Day 28
|
|
Evaluate the effect on circulating tumor cells
Časové okno: Completion of treatment
|
Determined by the commerical Immunocon cell search assay
|
Completion of treatment
|
Compare outcome of patients receiving letrozole and PTK787/ZK222584 (cases) with control patients from pivotal trials of letrozole in the first and second line setting.
Časové okno: 30 days after completion of study treatment
|
Matching the cases and controls for line of therapy, sites of disease and duration of prior aromatase inhibitor therapy before the study patient initiates PTK787/ZK222584 treatment.
|
30 days after completion of study treatment
|
Evaluate polymorphisms in relevant drug metabolism genes to determine the molecular basis for interactions between letrozole and PTK787/ZK222584 should they occur.
Časové okno: Completion of treatment
|
Completion of treatment
|
|
Correlate serum LDH level with clinical response
Časové okno: Completion of treatment
|
Completion of treatment
|
|
With additional patient consent, collect peripheral blood cells, serum, plasma, and representative tumor tissue specimens for future correlative science studies
Časové okno: Baseline visit
|
Baseline visit
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Cynthia Ma, M.D., Ph.D., Washington University School of Medicine
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Kožní choroby
- Novotvary
- Novotvary podle místa
- Nemoci prsu
- Novotvary prsu
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Inhibitory enzymů
- Antineoplastická činidla
- Hormony, hormonální náhražky a antagonisté hormonů
- Inhibitory proteinkinázy
- Antagonisté hormonů
- Inhibitory aromatázy
- Inhibitory syntézy steroidů
- Antagonisté estrogenu
- Letrozol
- Vatalanib
Další identifikační čísla studie
- 05-0970
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Novotvary prsu
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital a další spolupracovníciDokončenoPrůvodce klinickou aplikací Conebeam Breast CTČína
-
Gangnam Severance HospitalNáborHER2 Enriched Subtype Cancer Breast, Herzuma, PAM50 StudyKorejská republika
-
BioNTech SESeventh Framework ProgrammeDokončenoRakovina prsu (Triple Negative Breast Cancer (TNBC))Švédsko, Německo
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Zatím nenabírámeAnatomický karcinom prsu stadia II AJCC v8 | Anatomický karcinom prsu stadia III AJCC v8 | Rané stadium karcinomu prsu | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Spojené státy
-
Emory UniversityNational Cancer Institute (NCI)StaženoPrognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v mozku | Metastatický karcinom prsu | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktivní, ne náborAnatomický karcinom prsu stadia IV AJCC v8 | Prognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v kosti | Metastatický maligní novotvar v lymfatických uzlinách | Metastatický maligní novotvar v játrech | Metastatický karcinom prsu | Metastatický maligní novotvar v plicích | Metastatický... a další podmínkySpojené státy, Kanada, Saudská arábie, Korejská republika
Klinické studie na Letrozol
-
Rovi Pharmaceuticals LaboratoriesNábor
-
Institut du Cancer de Montpellier - Val d'AurelleNovartisDokončeno
-
Helsinki University Central HospitalFoundation for Paediatric Research, FinlandDokončenoÚstavní zpoždění růstu a pubertyFinsko
-
University of Alabama at BirminghamGenentech, Inc.; Breast Cancer Research FoundationDokončenoRakovina prsu | Novotvar prsu | Rakovina prsuSpojené státy
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerDokončenoNovotvary prsu
-
Xuanzhu Biopharmaceutical Co., Ltd.Zatím nenabírámePokročilá rakovina prsuČína
-
Assiut UniversityNáborNeplodnost, ženaEgypt
-
Fudan UniversityNáborEndometriální rakovinaČína
-
Affiliated Hospital of Nantong UniversityZatím nenabíráme
-
Ahon Pharmaceutical Co., Ltd.NáborPokročilá rakovina prsu | Rakovina prsu u ženČína